. 2020 Jan 31;77(19):3693–3710. doi: 10.1007/s00018-020-03459-1

Table 3.

Completed clinical studies of PD-L1 inhibitors

mAb alone/combination	Phase	Setting	Result	NTC
Avelumab ± enzalutamide	I	mCRPC patients whose diseases progressed on ADT	Well tolerated Prolonged PSA doubling time: 17% (3/17) SD: 80% (4/ 5)	-
Atezolizumab	Ia	mCRPC patients who had received enzalutamide and/or Provenge	PSA₅₀ response rate: 13% (2 /15) Median survival: 15.8 months Median PFS: 3.4 months OSR: 12 months (55.6%)	NCT01375842
Durvalumab + olaparib	II	mCRPC patients who had received either abiraterone or enzalutamide	PSA₅₀ response: 44% (7/16) BRCA2 mutation: 35% (6/17) PSA₅₀ response in BRCA2⁺ cases: 83% (5/6) Median PFS: 7.8 months	NCT02484404

mAb alone/combination

Phase

Setting

Result

NTC

Avelumab ± enzalutamide

mCRPC patients whose diseases progressed on ADT

Well tolerated

Prolonged PSA doubling time: 17% (3/17)

SD: 80% (4/ 5)

Atezolizumab

mCRPC patients who had received enzalutamide and/or Provenge

PSA₅₀ response rate: 13% (2 /15)

Median survival: 15.8 months

Median PFS: 3.4 months

OSR: 12 months (55.6%)

Durvalumab + olaparib

mCRPC patients who had received either abiraterone or enzalutamide

PSA₅₀ response: 44% (7/16)

BRCA2 mutation: 35% (6/17)

PSA₅₀ response in BRCA2⁺ cases: 83% (5/6)

Median PFS: 7.8 months